Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rosetta Genomics Limited has reported that its US-based subsidiary Rosetta Genomics has received a license from Roche Molecular Systems to use its PCR technology in the company’s microRNA-based diagnostic tests.
Subscribe to our email newsletter
Rosetta Genomics has developed a custom designed, highly sensitive and specific microRNA detection platform which is based on Roche PCR technology. This proprietary platform is said to help Rosetta Genomics identify microRNA biomarkers in several sample types and body fluids, with very high sensitivity and specificity.
Amir Avniel, president and CEO of Rosetta Genomics, said: “We have now been granted licenses from both Roche and Nanogen for use of their respective PCR technologies for diagnostic use, and are looking forward to the launch of our first microRNA-based diagnostic tests in 2008”.